A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

Inclusion Criteria

• •Male and female subjects =/\> 16 years of age (or minimum age required in a given country) with history of HBeAg-positive chronic hepatitis B infection;
• •Incomplete response to current lamivudine therapy;
• •HBeAg-positive;
• •Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis D virus (HDV);
• •Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease.